[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622924":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":18,"responsibleParty":25,"collaborators":18,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":35,"eligibilityCriteria":36,"healthyVolunteers":31,"sex":37,"minAge":38,"maxAge":18,"enrollmentInfo":39,"targetDuration":18,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":18,"overallStatus":48,"whyStopped":18,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":18},{"fullName":5,"class":6},"University of Luebeck","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Catheter ablation for atrial fibrillation plus semaglutide","EXPERIMENTAL","Catheter ablation for atrial fibrillation plus semaglutide (up to 2.4 mg weekly)",[13],"Drug: Semaglutide (SEMA)",{"label":15,"type":16,"description":17,"interventionNames":18},"Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapy","NO_INTERVENTION","Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapy (standard therapy)",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Semaglutide (SEMA)","Catheter ablation for AF plus semaglutide (up to 2.4 mg weekly)",[9],{"type":26,"investigatorFullName":27,"investigatorTitle":28,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Roland Richard Tilz, MD","Director, Department of Rhythmology","100622924","phase-4-semaglutide-prior-to-catheeter-ablation-in-patients-with-atrial-fibrillation-100622924",false,"NCT07389941","Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation","Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF)","SPICE-AF","Inclusion criteria:\n\n* Age 18-80 years\n* Symptomatic paroxysmal or persistent AF eligible for first-time catheter ablation\n* Body mass index ≥30 kg\u002Fm or body mass index ≥28 kg\u002Fm plus ≥1 weight-related comorbidity\n* No prior treatment with glucacon-like peptide-1 receptor agonists\n\nExclusion criteria:\n\n* Current use of glucacon-like peptide-1 receptor agonists or dipeptidyl peptidase 4 inhibitors or use within the last 90 days prior to screening\n* Current antiobesity medication use or use within the last 90 days prior to screening\n* A self-reported change in body weight of \\>5 kg within 30 days before screening\n* History of bariatric surgery\n* History of diabetes mellitus\n* Hospitalization for unstable angina, or transient ischemic attack \\\u003C30 days prior to screening\n* Pulmonary embolism \\\u003C90 days before screening\n* Myocardial infarction, or stroke \\\u003C90 days prior to screening\n* Uncontrolled thyroid disease: thyroid-stimulating hormone \\>10.0 mIU\u002FL or \\\u003C0.4 mIU\u002FL at screening\n* Active malignancy\n* Acute pancreatitis \\\u003C180 days before screening\n* History or presence of chronic pancreatitis\n* Chronic kidney disease with creatinine clearance \\\u003C30 mL\u002Fmin\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\n* Chronic inflammatory conditions requiring immunosuppression and\u002For on glucocorticoids\n* Pregnancy, breast-feeding or planning pregnancy","ALL","18 Years",{"count":40,"type":41},240,"ESTIMATED","INTERVENTIONAL",[44],"PHASE4","To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.",[47],"Atrial Fibrillation (AF)","NOT_YET_RECRUITING","2026-02-08",{"date":51,"type":52},"2026-02-11","ACTUAL",{"date":54,"type":41},"2026-10",{"date":56,"type":41},"2029-04",{"name":5,"class":6}]